Graham Capital Management’s CorMedix CRMD Stock Holding History

Graham Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-92,151	Closed	-$1.07M	–	1280
2025 Q3	$1.07M	Buy	92,151 +29,703	+48%	+$359K	0.02%	369
2025 Q2	$769K	Sell	62,448 -42,746	-41%	-$472K	0.01%	669
2025 Q1	$648K	Buy	+105,194	New	+$1.09M	0.01%	699

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Graham Capital Management's CRMD Position: Q4 2025 in Review

Graham Capital Management sold out of CorMedix (CRMD) in Q4 2025, closing a stake of 92,151 shares — an estimated $1.07M sold.

Graham Capital Management first reported a position in CRMD in Q1 2025 and held it in 3 quarters. The position peaked at $1.07M in Q3 2025. 198 funds tracked by Wall St. Rank hold CRMD as of Q4 2025.

Graham Capital Management reported no remaining CorMedix position as of Q4 2025 after selling out during the quarter.
Graham Capital Management sold 92,151 CorMedix shares in Q4 2025, an estimated $1.07M.
Graham Capital Management first reported a position in CorMedix in Q1 2025 and held it in 3 quarters.
Graham Capital Management's CorMedix position peaked at $1.07M in Q3 2025.
198 funds tracked by Wall St. Rank held CorMedix as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.